Altimmune Inc (NASDAQ: ALT), which develops immunotherapies and vaccines, is seeing its stock surge on 15 times its average volume after the company reported the results of a midstage study of its lead candidate NasoVAX.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,